Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a sharp stock decline after Novo Nordisk's (NYSE:NVO) mid-stage data on its obesity drug.
Andres Maldonado of H.C. Wainwright reiterated a Buy rating for Corbus with an $80 price target, highlighting that Novo's recent challenges with monlunabant, a drug targeting the same receptor as Corbus' CRB-913, should not impact the latter's potential. The stock currently trades below the $20 mark.
Maldonado stressed that different drugs within the same class could exhibit unique efficacy and safety profiles.
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can't afford to miss out if you're serious about the business.
Oppenheimer And Mizuho Double Down On Corbus' Pipeline
Oppenheimer also maintained a Buy rating, setting a price target of $88, focusing not only on CRB-913 but also on Corbus' broader assets, especially CRB-701.
Mizuho similarly recommended buying the dip, viewing the recent 60% stock plunge as an overreaction.
The firm pointed to CRB-701's positive Phase 1 data and sees the company's valuation primarily tied to this Nectin-4-based ADC for cancer treatment, rather than the obesity drug alone.
Corbus Pharmicals Holdings, Inc.(納斯達克股票代碼:CRBP)本週收到了H.C. Wainwright和Oppenheimer重申的買入評級,儘管諾和諾德(紐約證券交易所代碼:NVO)公佈了肥胖藥物的中期數據,但該公司的多元化產品線是未來增長的關鍵驅動力。
H.C. Wainwright的安德烈斯·馬爾多納多重申了對Corbus的買入評級,目標股價爲80美元,他強調Novo最近對monlunabant(一種靶向與Corbus的CRB-913相同的受體的藥物)所面臨的挑戰不應影響後者的潛力。該股目前的交易價格低於20美元大關。
馬爾多納多強調,同一類別中的不同藥物可能表現出獨特的療效和安全性。
- 每天在收件箱中免費獲取Benzinga的獨家分析以及有關大麻行業和市場的熱門新聞。在這裏訂閱我們的時事通訊。如果你認真對待這筆生意,就不能錯過這個機會。
奧本海默和瑞穗在 Corbus 的管道上雙管齊下
奧本海默還維持買入評級,將目標股價定爲88美元,不僅關注CRB-913,還關注Corbus的更廣泛資產,尤其是CRB-701。
瑞穗同樣建議逢低買入,將最近60%的股票暴跌視爲反應過度。
該公司指出了CRB-701的積極的第一階段數據,並認爲該公司的估值主要與這種基於Nectin-4的癌症治療ADC有關,而不僅僅是肥胖藥物。